InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
IMLFF InMed Pharmaceuticals Inc
HAL Halliburton Co
DPZ Domino's Pizza Inc
EQT EQT Corp
CLOEF Cloetta AB
CHH Choice Hotels International Inc
PRAC Productivity Technologies Corp
BAC Bank of America Corp
USAK USA Truck Inc
BABA Alibaba Group Holding Ltd
Go

Health Care : Biotechnology | Small Cap Growth
Based in Canada
Company profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Closing Price
$0.274
Day's Change
0.0446 (19.44%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.322
Day's Low
0.266
Volume
(Heavy Day)
Volume:
1,100,285

10-day average volume:
242,185
1,100,285
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Social data discovery, filtering, and analysis provided by LikeFolio: © SwanPowers, LLC

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

TD Ameritrade provides access to social media platforms on an "as is" basis, and cannot guarantee that content from social media is always available, that it contains all content from the social media source, or that it contains the most recent or most relevant information from the source.